Airsculpt Technologies, Inc. AIRS
Unless otherwise indicated or the context otherwise requires, references in this Annual Report on Form 10-K to the "Company," "AirSculpt," "we," "us" and "our" refer to AirSculpt Technologies, Inc. and its consolidated subsidiaries and the Professional Associations (as defined hereinafter).
AirSculpt is a next-generation body contouring treatment designed to optimize both comfort and precision, available exclusively at AirSculpt offices. The minimally invasive procedure removes fat and tightens skin, while sculpting targeted areas of the body, allowing for quick healing with minimal bruising, tighter skin, and precise results.
We believe our treatment results and elite patient experience have positioned AirSculpt as a preferred body contouring brand. We performed 11,852 body contouring procedures in 2025. Our proprietary and patented AirSculpt® method is minimally invasive because it requires no needle, no scalpel, no stitches and no general anesthesia to achieve transformational change that appears both natural and smooth. Our patients are guided by surgeons, nurses and patient care consultants through every step of the experience.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $151.8M | $180.3M | $195.9M | $168.8M | $133.3M | $62.8M | $41.2M | — |
| SG&A | $82.2M | $98.9M | $102.4M | $101.4M | $65.7M | $23.6M | $20.1M | — |
| Total operating expenses | $163.4M | $181.9M | $186.2M | $173.3M | $117.5M | $52.7M | $40.6M | — |
| Operating income | -$11.6M | -$1.6M | $9.7M | -$4.5M | $15.8M | $10.0M | $663.0K | — |
| Interest expense | $6.1M | $6.2M | $6.5M | $6.8M | $4.9M | $2.5M | $2.9M | — |
| Pre-tax income | -$17.6M | -$7.8M | $3.2M | -$11.3M | $10.9M | $7.6M | -$2.2M | — |
| Income tax | $6.0M | $188.0K | $7.5M | $3.4M | $329.0K | $0 | $0 | — |
| Net income | -$11.7M | -$8.0M | -$4.2M | -$14.7M | $10.6M | $7.6M | -$2.2M | — |
| EPS, basic | -0.19 | -0.14 | -0.08 | -0.26 | -0.01 | — | — | — |
| EPS, diluted | -0.19 | -0.14 | -0.08 | -0.26 | -0.01 | — | — | — |
| Shares, diluted (wtd. avg.) | 60.5M | 57.7M | 56.8M | 55.7M | 55.6M | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $8.4M | $8.2M | $10.3M | $9.6M | $25.3M | $10.4M | $5.1M | $5.4M |
| Total current assets | $15.5M | $17.1M | $16.0M | $16.7M | $29.4M | $11.6M | — | — |
| Property, plant and equipment | $27.8M | $37.5M | $28.9M | $24.2M | $13.6M | $7.1M | — | — |
| Goodwill | $81.7M | $81.7M | $81.7M | $81.7M | $81.7M | $81.7M | — | — |
| Other intangibles | $36.8M | $41.6M | $46.3M | $51.1M | $55.9M | $60.6M | — | — |
| Total assets | $187.3M | $212.8M | $204.0M | $200.8M | $200.6M | $179.6M | — | — |
| Accounts payable | $5.4M | $6.3M | $3.9M | $3.8M | $2.7M | $1.1M | — | — |
| Short-term debt | $5.5M | $4.2M | $2.1M | $2.1M | $850.0K | $400.0K | — | — |
| Total current liabilities | $27.9M | $28.9M | $20.3M | $22.3M | $16.4M | $9.5M | — | — |
| Long-term debt | $50.6M | $65.5M | $69.5M | $81.4M | $81.8M | $32.1M | — | — |
| Total liabilities | $99.6M | $134.6M | $120.0M | $130.0M | $117.0M | $55.9M | — | — |
| Retained earnings | -$40.6M | -$28.9M | -$19.6M | -$15.1M | -$393.0K | — | — | — |
| Total equity | $87.7M | $78.2M | $82.7M | $70.8M | $83.5M | — | — | — |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $3.1M | $11.3M | $24.0M | $24.4M | $26.6M | $14.0M | $4.9M | — |
| Depreciation and amortisation | $12.8M | $11.9M | $10.3M | $8.1M | $6.6M | $5.6M | $5.0M | — |
| Stock-based compensation | $2.3M | $3.8M | $18.2M | $29.5M | $7.2M | $325.0K | $341.0K | — |
| Capital expenditure | $2.4M | $14.0M | $9.9M | $12.9M | $7.1M | $3.7M | $4.4M | — |
| Investing cash flow | -$2.4M | -$14.0M | -$9.9M | -$12.9M | -$7.1M | -$3.7M | -$4.4M | — |
| Financing cash flow | -$478.0K | $630.0K | -$13.4M | -$27.3M | -$4.5M | -$5.0M | -$783.0K | — |
| Dividends paid | $0 | $252.0K | $385.0K | $23.2M | $0 | $0 | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001870940-26-000021.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $41.2M | $62.8M | $133.3M | $168.8M | $195.9M | $180.3M | $151.8M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$2.2M | $7.6M | $10.6M | -$14.7M | -$4.2M | -$8.0M | -$11.7M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Results announced Item 2.02
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Results announced Item 2.02
- Officer or director change Item 5.02
- Officer or director change Item 5.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8011
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| HIMS | Hims & Hers Health, Inc. | $6.42B | 54.3x | 59.0% |
| TDOC | Teladoc Health, Inc. | $1.15B | — | -1.5% |
| STLN | Starling Oncology, Inc. | $683.9M | — | 27.8% |
| SBC | SBC Medical Group Holdings Inc | $543.0M | 10.6x | -15.5% |
| LFMD | LifeMD, Inc. | $102.7M | 8.5x | 25.3% |
| CCM | Concord Medical Services Holdings Ltd | — | — | 26.6% |
| BMGL | Basel Medical Group Ltd | — | — | — |